Source: Fortune.com
Summary
The COVID pandemic exposed weaknesses in Europe’s critical supply chains, particularly in the pharmaceutical industry. Despite the challenges, there is a growing recognition among business and political leaders of the need to address these vulnerabilities. However, translating this awareness into action is proving difficult. The industry is calling for a more sustainable and secure approach to supply chain management, rather than just focusing on cost reduction.
Our Reading
The numbers tell one story. Europe’s pharmaceutical industry is heavily reliant on imports from China and India, with almost all key starting materials coming from these countries. The industry is warning that the pursuit of lower costs has compromised the security of supply, and that the economic incentives for long-term capital investments are not there. The COVID pandemic showed that it is possible to find solutions to these problems, but the challenge is to make these solutions sustainable.
The announcement sounds familiar. Companies are warning about the risks of supply chain disruptions, but the response is often too little, too late. The industry is calling for a more proactive approach to supply chain management, rather than just reacting to crises as they occur. The challenge is to balance the need for cost reduction with the need for security and sustainability.
The strategy enters a familiar phase. The industry is at a crossroads, and the choices made now will determine the future of Europe’s pharmaceutical supply chains. The question is whether the industry will continue down the path of cost reduction, or whether it will prioritize security and sustainability. The answer will depend on the economic incentives and the regulatory environment.
Original observation: The pursuit of lower costs has become a threat to the security of supply, and the industry is now facing a crisis of its own making.
Author: Evan Null
